Challenges in the design and conduct of phase III brain tumor therapy trials
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Twenty years ago a phase III trial by the Brain Tumor Study Group demonstrated that surgery and radiation were better treatment for malignant glioma than surgery alone.1 Maximal surgical resection and conventional radiotherapy quickly became the standard of care for patients with high-grade glioma. Since then many other treatments, most often cytotoxic drugs,2 have been added to surgery and radiation, and compared with standard therapy in randomized controlled trials(RCTs). None has unequivocally prolonged tumor control or patient survival.3 While these failures speak largely to the resilient nature of malignant glioma, certain issues surrounding the initiation and conduct of phase III trials of brain tumor treatment have surfaced in recent years and warrant discussion before the next generation of antiglioma therapies are tested. Some RCTs were based on inconclusive phase II data and may have been initiated prematurely, while others had divergent entry criteria, inadequate control for prognostic factors, and different outcome measures. Moreover, few studies evaluated quality of life (QOL), toxicity, or cost in a comprehensive way and none considered patient preferences for treatment. In this report we describe methods of assessing the results of phase II trials as a means of selecting treatments that most warrant phase III evaluation, and discuss challenges in the design and conduct of RCTs of new therapies for malignant glioma.
When is an RCT warranted? When are the results of a phase II study sufficiently compelling to warrant a randomized trial? Randomized controlled trials are initiated when new treatments are found to have antiglioma activity in phase II evaluation. Phase II trials are of two types:(1) those that measure tumor response and (2) those that measure tumor control. In studies of response, treatment is given to patients with visible tumor, and the rate and duration of the response is recorded. …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Views & Reviews
Outcome in adult low-grade gliomaThe impact of prognostic factors and treatmentDavid Schiff, Paul D. Brown, Caterina Giannini et al.Neurology, September 24, 2007 -
Special Articles: Invited Articles
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomasWarren P. Mason, J. Gregory Cairncross et al.Neurology, July 28, 2008 -
Views & Reviews
Paradoxes of evidence-based medicine in lower-grade gliomaTo treat the tumor or the patient?Hugues Duffau et al.Neurology, August 29, 2018 -
Article
Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV fociAmélie Darlix, Valérie Rigau, Julien Fraisse et al.Neurology, January 22, 2020